Indicearticolo originale
FDA Approves Larger Size Intacs
Corneal Implants For Keratoconus
Addition Technology, Inc., the maker of Intacs corneal implants, AlphaSphere
orbital implants and the AlphaCor artificial cornea, announced today FDA approval for an expanded range of additional sizes of Intacs corneal implants for keratoconus.
Addition Technology, Inc.
Addition Technology, Inc.
FOR IMMEDIATE RELEASE
PR Log (Press Release) – Apr 07, 2010 – Des Plaines, Illinois, April 7, 2010 – Addition Technology, Inc., the maker of Intacs corneal implants, AlphaSphere orbital implants and the AlphaCor artificial cornea, announced today that it has received FDA approval for an expanded range of additional sizes of Intacs corneal implants for keratoconus.
“The availability of the larger sizes in the US expands its use when treating keratoconus patients. In my practice, where we manage over 1,000 keratoconic patients, I can definitely see a broader subsection of patients benefiting from these new Intacs sizes,” said Yaron S. Rabinowitz, M.D., Director of eye research at the Cedar Sinai Medical Center, Los Angeles, and clinical professor of ophthalmology, University California, Los Angeles. “I have been pleased with the results and now see this as an additional option to delay or avoid a corneal transplant for keratoconic patients.”
David Schanzlin, M.D., of Shiley Eye Clinic, La Jolla, CA, one of the original FDA medical monitors and first US surgeon to work with Intacs for keratoconus pioneer Prof. Joseph Colin, said, “Our colleagues in Europe have been presenting data for over 10 years regarding the benefits of the larger sizes. Based on the impressive results they have reported, I view this as an important breakthrough in addressing keratoconus, particularly in younger people where a transplant may not always be the first option.”
“We are pleased to receive FDA approval at this time. As a company, we have been studying and surveying the keratoconus market for more than ten years. We have learned that surgeons need more options when dealing with these unique and challenging cases. The expansion in our product offering will go a long way toward addressing this need on behalf of the surgeon and their patients,” said William M. Flynn, president and chief executive officer.
Addition Technology, Inc., a privately held eye care company, specializes in novel solutions for sight-threatening eye indications. Intacs and Intacs SK corneal implants, AlphaCor artificial cornea and AlphaSphere orbital implant are patented devices, and the first of their kind, approved by FDA and granted CE Mark certification in Europe. Intacs cornea implants are indicated for keratoconus and myopia. AlphaCor artificial cornea is indicated as an alternative for high-risk, repeat graft failures. AlphaSphere orbital implant is indicated to replace the eye due to loss related to trauma or disease. All products are distributed worldwide.
Visit www.AdditionTechnology.com for more information.
# # #
Addition Technology, Inc. is a privately held eye care company, specializing in novel solutions for sight-threatening eye indications.
FDA Approves Larger Size Intacs
Corneal Implants For KeratoconusAddition Technology, Inc., the maker of Intacs corneal implants, AlphaSphere
orbital implants and the AlphaCor artificial cornea, announced today FDA approval for an expanded range of additional sizes of Intacs corneal implants for keratoconus.Addition Technology, Inc.
Addition Technology, Inc.
FOR IMMEDIATE RELEASE
PR Log (Press Release) – Apr 07, 2010 – Des Plaines, Illinois, April 7, 2010 – Addition Technology, Inc., the maker of Intacs corneal implants, AlphaSphere
orbital implants and the AlphaCor artificial cornea, announced today that it has received FDA approval for an expanded range of additional sizes of Intacs corneal implants for keratoconus.“The availability of the larger sizes in the US expands its use when treating keratoconus patients. In my practice, where we manage over 1,000 keratoconic patients, I can definitely see a broader subsection of patients benefiting from these new Intacs sizes,” said Yaron S. Rabinowitz, M.D., Director of eye research at the Cedar Sinai Medical Center, Los Angeles, and clinical professor of ophthalmology, University California, Los Angeles. “I have been pleased with the results and now see this as an additional option to delay or avoid a corneal transplant for keratoconic patients.”
David Schanzlin, M.D., of Shiley Eye Clinic, La Jolla, CA, one of the original FDA medical monitors and first US surgeon to work with Intacs for keratoconus pioneer Prof. Joseph Colin, said, “Our colleagues in Europe have been presenting data for over 10 years regarding the benefits of the larger sizes. Based on the impressive results they have reported, I view this as an important breakthrough in addressing keratoconus, particularly in younger people where a transplant may not always be the first option.”
“We are pleased to receive FDA approval at this time. As a company, we have been studying and surveying the keratoconus market for more than ten years. We have learned that surgeons need more options when dealing with these unique and challenging cases. The expansion in our product offering will go a long way toward addressing this need on behalf of the surgeon and their patients,” said William M. Flynn, president and chief executive officer.
Addition Technology, Inc., a privately held eye care company, specializes in novel solutions for sight-threatening eye indications. Intacs
and Intacs SK corneal implants, AlphaCor artificial cornea and AlphaSphere orbital implant are patented devices, and the first of their kind, approved by FDA and granted CE Mark certification in Europe. Intacs cornea implants are indicated for keratoconus and myopia. AlphaCor artificial cornea is indicated as an alternative for high-risk, repeat graft failures. AlphaSphere orbital implant is indicated to replace the eye due to loss related to trauma or disease. All products are distributed worldwide.Visit www.AdditionTechnology.com for more information.
# # #
Addition Technology, Inc. is a privately held eye care company, specializing in novel solutions for sight-threatening eye indications.
